SCHEMBL5652087

SCHEMBL5652087

Cc1cc(C(=O)NCCCN)ccc1-c1nc2c(C)cccc2[nH]1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FLT3 P36888 5/20 0.49
MGAM O43451 7/20 0.48
GAA P10253 7/20 0.48
SI P14410 7/20 0.48
MGAM2 Q2M2H8 7/20 0.48
APLNR P35414 1/20 0.46
KDM4E B2RXH2 2/20 0.45
HSD17B10 Q99714 2/20 0.45
VSIR Q9H7M9 1/20 0.45
HPSE Q9Y251 2/20 0.44
GRIN1 Q05586 1/20 0.43
GRIN2A Q12879 1/20 0.43
GRIN2B Q13224 1/20 0.43
MAPK8 P45983 1/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TP53 P04637 1/20 0.43
HPGD P15428 1/20 0.43
RAB9A P51151 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5650962 0.92 MGAM (0.51) FLT3MGAMGAASIMGAM2
SCHEMBL5651896 0.92 FLT3 (0.48) FLT3MGAMGAASIMGAM2
SCHEMBL5650424 0.91 HPSE (0.50) FLT3MGAMGAASIMGAM2
SCHEMBL5649719 0.89 MGAM (0.48) FLT3MGAMGAASIMGAM2
SCHEMBL5648785 0.88 HPSE (0.53) FLT3MGAMGAASIMGAM2
SCHEMBL5652419 0.86 HPSE (0.57) FLT3MGAMGAASIMGAM2
SCHEMBL5650407 0.86 APLNR (0.47) MGAMGAASIMGAM2APLNR
SCHEMBL5652092 0.84 FLT3 (0.49) FLT3APLNRKDM4EHSD17B10GRIN1
SCHEMBL5652617 0.83 FLT3 (0.45) FLT3KDM4EHSD17B10HPSEGRIN1
SCHEMBL5651518 0.83 FLT3 (0.53) FLT3KDM4EHSD17B10GRIN1GRIN2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7220769-B2 Azolylbenzamides and analogues and their use for treating osteoporosis NIKEM RESEARCH S.R.L. (IT) 2007-05-22 US disclosed
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis 3-V BIOSCIENCES, INC. 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038095-A1 Azolylbenzamides and analogues and their use for treating osteoporosis NR0B2, NR0B1, NCOR1 FLT3 1968/4885MGAM 3224/4885GAA 4139/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.